Boehringer Ingelheim Launches Affordable Biosimilar of Humira, Offering Significant Cost Savings

Germany’s pharmaceutical company, Boehringer Ingelheim, has introduced an unbranded version of its biosimilar of AbbVie’s blockbuster rheumatoid arthritis drug, Humira. This new biosimilar is priced at a remarkable 81% discount compared to the original drug, providing significant cost savings for patients. Boehringer Ingelheim’s biosimilars have received the distinction of being designated as interchangeable by the U.S. Food and Drug Administration, making them the only alternatives to Humira that can be substituted without consulting the prescriber.

In July, Boehringer Ingelheim launched a branded biosimilar called Cyltezo, priced at a 5% discount to Humira’s current list price. However, the company recognized the need for a lower-cost version to cater to pharmacy benefit managers (PBMs) seeking cheaper Humira biosimilars for their formulary. Additionally, healthcare systems that act as both insurer and provider often do not pursue after-market discounts, and Boehringer Ingelheim aims to address this by offering a more affordable option.

Other companies, including Novartis’ Sandoz and Amgen, have also introduced Humira biosimilars with dual pricing tiers. Sandoz’s Hyrimoz is available at a 5% discount, while the unbranded version offers an 81% discount. However, experts suggest that heavily discounted versions of Humira may not be widely accessible due to potential reluctance from PBMs, which control a significant portion of the prescription drug market.

Boehringer Ingelheim’s approach of providing dual pricing aims to ensure that biosimilars are accessible to as many patients as possible. By offering affordable alternatives, the company hopes to encourage the adoption of biosimilars and contribute to reducing healthcare costs.

While the availability of discounted Humira biosimilars may face challenges, the introduction of more affordable options represents a positive step towards increasing access to vital medications for patients in need. Boehringer Ingelheim’s commitment to offering cost-effective alternatives demonstrates their dedication to improving patient outcomes and making healthcare more affordable.